EUCTR2014-005518-44-DE进行中（未招募）1 期
Double-blind, randomised clinical study comparing efficacy and safety of Gentamicin 0.1%_Betamethasone 0.05% Cream (Test) vs. Diprogenta(R) Cream (Reference) vs. Vehicle in patients with bacterial infected eczema
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Women and men = 18 years of age
- •2) Written consent to study participation after patient information by the investigator
- •3) Diagnosis of bacterial infected eczema based on clinical symptoms in a treatment area between 5 and 25 cm2
- •4) At least moderately severe clinical picture, i.e. patients must have a SIRS score = 8. The SIRS (Skin Infection Rating Scale) score is defined as the sum score of the 7 clinical parameters exudate/pus, crusting, erythema, tissue warmth, tissue oedema, itching and pain (each symptom assessed on a scale ranging from 0 (=absent) to 6 (=severe)).
- •5) Presence of the clinical parameter exudate/pus (i.e. score =1)
- •6) For women of childbearing potential: Application of an efficient contraceptive method (according to guideline CPMP/ICH/286/95) during the whole study
- •7) For women of childbearing potential: Pregnancy test with negative result prior to study start.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 400
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Presence of a bacterial skin infection which, due to general criteria like severity or depth of the infection, cannot be treated adequately with topical antibiotics alone
- •2) Presence of any of the following skin conditions in the treatment area: viral infections (e.g. herpes simplex, herpes zoster), dermatomycosis, lues or tuberculosis of the skin, inoculation reactions, rosacea or rosacea-like dermatitis
- •3) Necessity of application of the study medication in the area around the eyes
- •4) Necessity of application of the study medication in the area around the ears
- •5) Necessity of application of the study medication near mucous membranes
- •6) Systemic therapy with antibiotics within the last 4 weeks before study inclusion
- •7) Systemic therapy with immunosuppressants or corticoids or medication with neuromuscular blocking effect within the last 2 weeks before study inclusion
- •8) Local treatment in the test area within the last week before inclusion
- •9) Known intolerance or hypersensitivity against gentamicin or other aminoglycosids, betamethasone or other glucocorticoids, chlorocresol, parabenes or any of the other ingredients in the study medications
- •10) Advanced renal insufficiency
- •11) Concomitant diseases like e.g. Myasthenia gravis, Parkinson or other neuromuscular disorders
- •12) Other severe acute or chronic concomitant disease with severe impairment of the general condition
- •13) Other concomitant diseases which may - taking the present knowledge into account - influence the parameters evaluated in the study in a way that an objective evaluation would be impossible
- •14) Necessity for a concomitant medication with neuromuscular blocking effect, e.g. benzodiazepines, or other central or peripheral muscle relaxants
- •15) Other concomitant medication which may - taking the present knowledge into account - influence the methods of measurements used in ths study or the resulting data
- •16) Reasonable doubt concerning the co-operation of the patient
- •17) Participation in another clinical study within the last 30 days prior to inclusion in this study
- •18) Participation in this study at an earlier date
- •19) Women with existing or intended pregnancy or during lactation
研究者
相似试验
进行中（未招募）
1 期
Clinical study to compare two cutaneous emulsions with the active substance methylprednisolone aceponate 0.1% and one cutaneous emulsion without active substance for patients withatopic dermatitisAtopic dermatitisMedDRA version: 20.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2018-001743-31-DEDermapharm AG330
进行中（未招募）
1 期
Clincal study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and of one ointment without active substance for patients with chronic stable plaque psoriasisEUCTR2020-004081-19-DEDermapharm AG306
进行中（未招募）
1 期
Clinical study to compare the therapeutic effects of two ointments with the active substances clotrimazole and betamethasone dipropionate and of one ointment without active substance for patients with moderate to severely inflamed infection of the skin through yeast fungi.moderate to severely inflamed candidiasis of the skinMedDRA version: 20.0Level: LLTClassification code 10007159Term: Candidiasis of skin and nailsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-003790-65-DEDermapharm AG552
招募中
1 期
Clinical study to compare two cutaneous ointments with the active substance methylprednisolone aceponate 0.1% and one cutaneous ointment without active substance for patients with atopic dermatitisCTIS2024-514548-10-01Dermapharm AG330
进行中（未招募）
1 期
Clinical study to compare two creams with the active substance imiquimod and one cream without active substance for patients with actinic keratosisActinic keratosisMedDRA version: 20.0 Level: PT Classification code 10000614 Term: Actinic keratosis System Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2016-000712-15-DEDermapharm AG426